Patients undergoing completely resection of EGRF mutation-positive NSCLC
Staging ⅠB (with high risk factor) to ⅢA
PS\<2
Adequate hematological, biochemical and organ functions.
You may not be if
Systemic anticancer therapy prior to surgery, other malignancies before or during the study, any unstable illness, women who were pregnant or lactating.
Clareo Health | Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer
